Prior to testing the efficacy of PDE4 inhibitors in our murine model of lung fibrosis, we assessed the pharmacokinetics of Compound 1 with our planned dosing regimen in uninjured wild‐type mice. Here, PDE4A is linked to pulmonary fibrosis.